<DOC>
	<DOC>NCT02581020</DOC>
	<brief_summary>This study seeks to assess the durability of response and persistence of resistance to ombitasvir/ paritaprevir/ritonavir in Japanese participants who enrolled in a Phase 2 or 3 clinical study with these agents for the treatment of chronic hepatitis C.</brief_summary>
	<brief_title>The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Participants treated in Study M12536 or M13004 with the 2D regimen (ombitasvir/ paritaprevir/ ritonavir) and completed 48 weeks of followup, regardless of SVR achievement. Participants who agree to sign the informed consent Participants treated with a directacting antiviral agent (DAA) immediately after Study M12536 or M13004.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Observation</keyword>
	<keyword>Japanese</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Follow-up</keyword>
</DOC>